Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy.

Abstract

Although a small, uncontrolled, nonrandomized trial, this study showed that WT1 vaccine therapy for patients with gynecological cancer was safe and produced a clinical response.